Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom

• Published in: Vaccine Vol. 40; no. 14; pp. 2173 - 2183
• Main Authors: Daniels, Vincent, Saxena, Kunal, Patterson-Lomba, Oscar, Gomez-Lievano, Andres, Saah, Alfred, Luxembourg, Alain, Velicer, Christine, Chen, Ya-Ting, Elbasha, Elamin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 25.03.2022; Elsevier Limited
• Subjects: (max 6): single dose; Age; Allergy and Immunology; Alphapapillomavirus; Cancer; Cancer vaccines; Clinical trials; Cost analysis; Cost-Benefit Analysis; Cost-effectiveness; developed countries; discount rate; disease models; Disease transmission; Dosage; durability; Economic models; Economics; Female; Females; Girls; Health impact; Health risks; HPV vaccine; Human papillomavirus; Humans; Infections; Male; Males; Papillomaviridae; Papillomavirus Infections - epidemiology; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines; Penis; prices; Quality-Adjusted Life Years; Quantiles; risk; Sensitivity analysis; Statistical analysis; Uncertainty; United Kingdom; United Kingdom - epidemiology; Uterine Cervical Neoplasms - epidemiology; Uterine Cervical Neoplasms - prevention & control; Vaccination; Vaccine effectiveness; Vaccines; Vagina; United Kingdom; United Kingdom > UK; NMB; HIC; ICER; CIN; (max 6): single dose; HPV vaccine; HPV; RRP; Health impact; WTP; Vaccine effectiveness; LMIC; QALY; DTM; Cost-effectiveness; PSA; Human papillomavirus; Recurrent respiratory papillomatosis; Cervical intraepithelial neoplasia; Probabilistic sensitivity analysis; High-income country; Dynamic transmission model; Willingness to pay; Incremental cost-effectiveness ratio; Low/middle-income country; Net monetary benefit; quality-adjusted life year

Although no human papillomavirus (HPV) vaccine is indicated for single-dose administration, some observational evidence suggests that a 1-dose regimen might reduce HPV infection risk to that achieved with 2 doses. This study estimated the potential health and economic outcomes associated with switch...